Search | Clinical Trials Finder

Conditions: Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions: Midostaurin; Drug
Lead sponsor: Jason Robert Gotlib; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • St Louis, Missouri

Conditions: Distal Radius Fracture
Interventions: Sugar-tong splint, Short forearm cast; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: MK-8748, Aflibercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Orlando, Florida • Winter Haven, Florida • Hagerstown, Maryland + 8 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions: Dexamethasone, Resection, Stereotactic Radiosurgery; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glioblastoma, Glioblastoma, WHO Grade IV
Interventions: Temozolomide (TMZ), Optune System, Pembrolizumab; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Richter Syndrome
Interventions: Obinutuzumab, Ibrutinib, CHOP; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions: catridecacog; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 12
States / cities: Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Healthy
Interventions: Trivalent influenza virus vaccine live, intranasal; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 16
States / cities: Little Rock, Arkansas • Marietta, Georgia • Bardstown, Kentucky + 13 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more

Conditions: Systemic Sclerosis, SSc
Interventions: Occupational therapy, Home app intervention; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Primary Haemophagocytic Lymphohistiocytosis
Interventions: NI-0501; Biological
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 5 more

Conditions: Alzheimer Disease
Interventions: Intermittent theta burst stimulation; Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 40 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Alopecia Areata
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 14 more

Conditions: Forearm Fracture
Interventions: Lidocaine, Saline; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 17 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Wrinkle
Interventions: Tixel 2; Device
Lead sponsor: Physicians Laser and Dermatology Institute; Other
Eligibility: 35 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam Film-coated tablet, Brivaracetam oral solution; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina

Conditions: Acne
Interventions: apremilast; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Constipation
Interventions: Propofol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years to 6 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Non-Hodgkin
Interventions: Fludarabine, Cyclophosphamide, JCAR017; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 23
States / cities: Santa Monica, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions: Romiplostim; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Carotid Artery Calcification, Carotid Artery Diseases
Interventions: Carotid Intravascular Lithotripsy; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 19 more

Conditions: Prostate Cancer Screening
Interventions: Novel needle biopsy catheter (test); Device
Lead sponsor: Uro-1 Medical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Hardeeville, South Carolina

Conditions: Plaque Psoriasis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 125 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 33
States / cities: Mobile, Alabama • Bakersfield, California • Beverly Hills, California + 26 more

Conditions: Metastatic Breast Cancer, Neoplasms, Breast
Interventions: Investigational Cancer Drug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 30
States / cities: Chula Vista, California • Los Angeles, California • Poway, California + 24 more

Search by objective public record fields.

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction

A Prospective, Single Center, Single-Arm Clinical Study of 20 Participants to Reduce the Appearance of the Peri-orbital Wrinkles. Participants Will Receive up to Four Treatments With Tixel Every 4 Weeks. Follow-up Will Occur 1 Month and 3 Months Following Last Treatment.

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Apremilast in the Treatment of Moderate to Severe Acne

Effect of Propofol on Internal Anal Sphincter Pressure During ARM

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)

Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.